ReviewCancer cell international2025
Unraveling the role of the solute carrier family in hepatocellular carcinoma: mechanisms and therapeutic prospects.
Review in Cancer cell international, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
Abstract
The solute carrier (SLC) family is one of the largest families of membrane transport proteins, essential for cellular metabolism and communication. Studies have shown that the SLC family plays a critical role in the metabolic processes and intrinsic biological behaviors of hepatocellular carcinoma (HCC). SLC38s contribute to the progression of HCC through signaling pathways such as PI3K/AKT/mTOR and Wnt/β-catenin/MYC. The regulation of upstream factors like miR-10b-5p, the LINC01559-miR-511-SLC38A1 axis, miRNA-432, and other genes are also implicated in HCC development. Additionally, SLC7A11 influences the proliferation of HCC cells via pathways such as SMYD3/SLC7A11 and JAK/STAT/SLC7A11. Other members of the SLC family also play significant roles in HCC through various mechanisms. Given the importance of SLCs in HCC and the lack of a comprehensive understanding of their molecular mechanisms, this study explores metabolic alterations in liver cancer cells and their surrounding immune cells. It also examines how the metal ions in liver cancer impact HCC growth and the efficacy of anticancer immunotherapy. Furthermore, we discuss the vital role of SLCs as key transporters for the hepatic uptake of anionic anticancer drugs, highlighting novel therapeutic opportunities.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.